AC
IPXL

Aternalis Capital’s Impax Laboratories, Inc. IPXL Stock Holding History

Aternalis Capital’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-130,000
Closed -$5.56M – 24
2015
Q4 		$5.56M Buy
+130,000
New +$5.19M 3.65% 13

Other funds holding IPXL

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
HP
Hound Partners New York $799M AUM 9.54% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AG
Aravt Global New York $11.3M AUM 3.78% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PCM
Pennant Capital Management Summit, New Jersey $212M AUM 19.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Aternalis Capital's IPXL Position: Q1 2016 in Review

Aternalis Capital sold out of Impax Laboratories, Inc. (IPXL) in Q1 2016, closing a stake of 130,000 shares — an estimated $5.56M sold.

Aternalis Capital first reported a position in IPXL in Q4 2015 and held it in 1 quarter. The position peaked at $5.56M in Q4 2015. 194 funds tracked by Wall St. Rank hold IPXL as of Q1 2016.

  • Aternalis Capital reported no remaining Impax Laboratories, Inc. position as of Q1 2016 after selling out during the quarter.
  • Aternalis Capital sold 130,000 Impax Laboratories, Inc. shares in Q1 2016, an estimated $5.56M.
  • Aternalis Capital first reported a position in Impax Laboratories, Inc. in Q4 2015 and held it in 1 quarter.
  • Aternalis Capital's Impax Laboratories, Inc. position peaked at $5.56M in Q4 2015.
  • 194 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q1 2016.

Based on Aternalis Capital's 13F filing for Q1 2016, filed 16 May 2016.